gefitinib has been researched along with fulvestrant in 25 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (fulvestrant) | Trials (fulvestrant) | Recent Studies (post-2010) (fulvestrant) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,712 | 207 | 1,196 |
| Protein | Taxonomy | gefitinib (IC50) | fulvestrant (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.0061 | |
| Estrogen receptor | Rattus norvegicus (Norway rat) | 0.0059 | |
| Progesterone receptor | Homo sapiens (human) | 0.0002 | |
| Steroid hormone receptor ERR1 | Homo sapiens (human) | 0.002 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.006 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0104 | |
| Bile acid receptor | Homo sapiens (human) | 0.79 | |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 2.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barrow, D; Dutkowski, CM; Gee, JM; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Pamment, J | 1 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Kurebayashi, J; Okubo, S; Sonoo, H; Yamamoto, Y | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Kaplow, R | 1 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA | 1 |
| Chen, B; Cheng, D; Jordan, VC; Liu, H; Louis, TE; Osipo, C; Weichel, AK; Wing, LK | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Dering, J; Desai, AJ; Dubinett, SM; Finn, RS; Garon, EB; Hosmer, W; Kamranpour, N; Márquez-Garbán, DC; Pietras, RJ; Pitts, S; Slamon, DJ; von Euw, EM | 1 |
| Mehta, A; Tripathy, D | 1 |
| Chen, Q; Li, Q; Liu, J; Qian, X; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, R; Xu, T; Zheng, J | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| An, T; Bai, H; Ding, X; Duan, J; Li, Z; Liu, Z; Shen, Z; Sun, Y; Wang, J; Wang, S; Wang, Y; Wang, Z; Wu, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Acconcia, F | 1 |
6 review(s) available for gefitinib and fulvestrant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Gene Expression Regulation; Genes, erbB-1; Humans; Quinazolines; Signal Transduction | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
2 trial(s) available for gefitinib and fulvestrant
| Article | Year |
|---|---|
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
17 other study(ies) available for gefitinib and fulvestrant
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
Topics: Antineoplastic Agents; Breast Neoplasms; Cytological Techniques; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2001 |
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured | 2002 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Signal Transduction; Tumor Cells, Cultured | 2004 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Quinazolines | 2006 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays | 2008 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2013 |
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transfection; Up-Regulation | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; China; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2015 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |